$20.08
-1.2%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ALMS • NASDAQ
| Alumis Inc. Common Stock Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
REVENUE | ||||
24.1M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||
(3.5M) | (3.2M) | (0.0) | (250K) | |
20.6M | -3.2M | 0.0 | -250K | |
OPERATING INCOME | ||||
(447.8M) | (297.6M) | (158.2M) | (113.6M) | |
(91.9M) | (35.2M) | (20.5M) | (12.5M) | |
(386M) | (265.6M) | (137.7M) | (101.1M) | |
-427.2M | -300.8M | -158.2M | -113.9M | |
PRE-TAX INCOME | ||||
14.2M | 12M | 3.4M | 2M | |
-30.1M | -3.2M | (0.0) | (0.0) | |
175.3M | 6.5M | 3.2M | 1.9M | |
-251.9M | -294.2M | -155M | -111.9M | |
NET INCOME | ||||
-8.6M | (0.0) | (0.0) | (0.0) | |
-243.3M | -294.2M | -155M | -111.9M |
ALMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 18, 2026 | June 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 02, 2026 | January 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Continue your ALMS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.